1. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation
- Author
-
Elena Greco, M.Y. Tan, Ranjit Akolekar, L. Konstantinidou, Kypros H. Nicolaides, Jacques Jani, Francisca S. Molina, AlanF Wright, Neil O'Gorman, M. Tsavdaridou, Argyro Syngelaki, Walter Plasencia, Nicola Persico, Urszula Ajdacka, Juan Luis Delgado, Liona C. Poon, S. Galeva, Daniel L. Rolnik, G. Papaioannou, and David Wright
- Subjects
Mean arterial pressure ,medicine.medical_specialty ,030219 obstetrics & reproductive medicine ,Eclampsia ,Radiological and Ultrasound Technology ,Pregnancy-associated plasma protein A ,business.industry ,Obstetrics ,Obstetrics and Gynecology ,Gestational age ,General Medicine ,030204 cardiovascular system & hematology ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Reproductive Medicine ,medicine.artery ,Biomarker (medicine) ,Medicine ,Gestation ,Radiology, Nuclear Medicine and imaging ,business ,Uterine artery ,Survival analysis - Abstract
OBJECTIVE To examine the performance of screening for early, preterm and term pre-eclampsia (PE) at 11-13 weeks' gestation by maternal factors and combinations of mean arterial pressure (MAP), uterine artery (UtA) pulsatility index (PI), serum placental growth factor (PlGF) and serum pregnancy-associated plasma protein-A (PAPP-A). METHODS The data for this study were derived from three previously reported prospective non-intervention screening studies at 11 + 0 to 13 + 6 weeks' gestation in a combined total of 61 174 singleton pregnancies, including 1770 (2.9%) that developed PE. Bayes' theorem was used to combine the prior distribution of gestational age at delivery with PE, obtained from maternal characteristics, with various combinations of biomarker multiples of the median (MoM) values to derive patient-specific risks of delivery with PE at
- Published
- 2018